MDR postponed. By EU. Because of Corona.

Due to the SARS-CoV-2 pandemic, the EU has proposed to postpone the start of the new MDR by 1 year.

Due to the current SARS-CoV-2 pandemic, the European Authority proposed in the Official Journal of the EU on 3.4.2020 (CELEX number: 52020PC0144) to postpone the date of application of the new MDR Regulation 2017/745 by 1 year.

"Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending Regulation (EU) 2017/745 concerning medical devices as regards the date of application of certain of its provisions".[1]:

REASON. MDR.
1. CONTEXT OF THE PROPOSAL.
"Grounds for and objectives of the proposal".

"Regulation (EU) 2017/745 of the European Parliament and of the Council, adopted on 5 April 2017, established a new legal framework to ensure the smooth functioning of the internal market for medical devices covered by this Regulation, based on a high level of health protection for patients and users and taking into account small and medium-sized enterprises active in this sector".

"The COVID 19 outbreak and the accompanying public health crisis represent an unprecedented challenge for Member States and a heavy burden for national authorities, healthcare institutions, EU citizens and economic operators. The exceptional situation caused by the COVID 19 crisis requires significant additional resources as well as greater availability of vital medical devices*, which could not have been reasonably foreseen at the time of the adoption of Regulation (EU) 2017/745".

"This exceptional situation has serious consequences for several areas covered by Regulation (EU) 2017/745 and therefore Member States, health institutions, economic operators and the other parties concerned will most likely not be able to ensure the proper implementation and application of that Regulation, as set out in it, from 26 May 2020".

"In order to ensure the proper functioning of the internal market, a high level of protection of public health and patient safety, to establish legal certainty and to avoid potential market disturbances, it is necessary to postpone the application of certain provisions of Regulation (EU) 2017/745 for one year. At the same time, it is necessary to postpone the date on which Directives 90/385/EEC and 93/42/EEC are to be repealed. These postponements will ensure that a functioning regulatory framework for medical devices will continue to exist after 26 May 2020. In addition, the proposed amendment aims to ensure that the Commission is able, at the earliest possible stage, to adopt Union-wide derogations in exceptional cases in response to national derogations in order to effectively address any shortages of essential medical devices across the Union".

2. LEGAL BASIS, SUBSIDIARITY AND PROPORTIONALITY. MDR.
Legal basis.

"The proposal is based on Article 114 and Article 168(4)(c) of the Treaty on the Functioning of the European Union (TFEU)".

Subsidiarity.

"In accordance with the principle of subsidiarity, Union action may be taken only if the objectives pursued cannot be attained by the Member States acting alone. Union action is necessary to ensure a high level of health protection for patients and users, the proper functioning of the internal market and the avoidance of potential market disturbances. The act to be amended was adopted in full compliance with the principle of subsidiarity and any amendments must be made by means of a Commission proposal".

Proportionality.

"Given the dimension of the current outbreak of COVID-19 and the accompanying public health crisis, this Union measure is necessary to achieve the objective of proper implementation and application of Regulation (EU) 2017/745 by all parties concerned. The proposed amendment aims to ensure that the purpose of Regulation (EU) 2017/745, namely to establish a sound, transparent, predictable and sustainable regulatory framework for medical devices that ensures a high level of protection of public health and patient safety and the proper functioning of the internal market for such devices, can be achieved'.

3. RESULTS OF THE EX-POST EVALUATION, STAKEHOLDER CONSULTATION AND IMPACT ASSESSMENT.

"This proposal is not accompanied by a separate impact assessment as this has already been carried out for Regulation (EU) 2017/745. The proposal does not change the substance of Regulation (EU) 2017/745 and does not impose any new obligations on the parties concerned. Its main purpose is to postpone the date of application of certain provisions of that Regulation by one year due to the exceptional circumstances related to the current COVID 19 outbreak".

4. IMPACT ON THE BUDGET.

"The proposal has no budgetary implications for the EU institutions".

(*2020/0060 (COD) recital (3): "Medical devices such as medical gloves, surgical masks, critical care equipment and other medical supplies play a crucial role in ensuring the health and safety of Union citizens and enabling Member States to provide patients with much-needed medical treatment in the face of the COVID 19 outbreak and the accompanying public health crisis").

WHEN WILL THE PROPOSAL BECOME LEGALLY BINDING?

2020/0060 (COD) recital (13):
"As the public health crisis associated with the COVID-19 outbreak absolutely requires immediate action, this Regulation should enter into force as soon as possible -".

For further details on the intended changes, please refer to the proposed amendment[1].

As soon as the measures[1][2] of the Member States transposing EU legal acts into national law, this information should be found under the link to the national transposition[3]

References. MDR.
  1. [1] Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending Regulation (EU) 2017/745 on medical devices as regards the date of application of some of its provisions https://eur-lex.europa.eu/search.html?type=named&qid=1586160245284&name=collection:eu-law-pre-acts-com accessed 6.4.2020.
  2. [2] EUROPEAN COMMISION, Brussels, 3.4.2020, COM(2020) 144 final; 2020/0060 (COD). "Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending Regulation (EU) 2017/745 on medical devices as regards the dates of application of certain of its provisions," https://ec.europa.eu/info/sites/info/files/proposal_for_a_regulation_of_the_european_parliament_and_of_the_council_amending_regulation_eu_2017_745_on_medical_devices_as_regards_the_dates_of_application_of_certain_of_its_provisions.pdf, accessed 3.04.2020.
  3. [3] National implementation,https://eur-lex.europa.eu/collection/n-law/mne.html, accessed 6.4.2020.

MDR Consulting Services needed?

Book our QuickCheck now.

How we support you with MDR Consulting Services.

  • Identification of the new requirements for your products (e.g. through reclassification)
  • Strategic advice on a roadmap for the compliance of your products after MDE
  • Support with labelling and introduction/maintenance of the UDI
  • Planning and preparation of approval documentation
  • Supply
  • Support a strategic plan for the submission of dossiers under MDR
  • Maintenance of product dossiers for sustainable compliance
  • Intensive stocktaking and analyses at different levels of depth
  • Identification of pain points
  • Creation of a strategy to close gaps quickly
  • Documentation control and creation over the life cycle of your products from design to production and approval, to post-market surveillance and post-market clinical follow-up (PMCF).
  • Risk-based assurance of the quality of your products with the help of pragmatic and individual solutions
  • Validation and qualification of your processes and systems
  • Strategic planning of clinical investigations and clinical follow-up, tailored to your product class
  • Preparation and support of the clinical documentation required under MDR

Share Article.

Facebook
Twitter
LinkedIn
XING
WhatsApp
Email

Persons to the article.

Dr Ralf Hess

Principal Consultant IVD

Dr. Ralf Hess studied biology at the Albert-Ludwigs-University of Freiburg, where he also completed his doctorate at the Institute of Virology. Dr. Hess has many years of experience in the development of medical devices and medicinal products and their combination, in laboratory analysis and quality assurance. The quality expert has set up, implemented and maintained QM systems in accordance with ISO and GxP for various areas of application. The customer service portfolio ranges from manufacturers of classical and biological drugs, medical device companies and vaccine manufacturers to immunohistochemical, immunological, molecular biological and serological diagnostic laboratories. Dr. Hess works worldwide as an auditor in the GxP/ISO area and has many years of experience in FDA remediation projects and the regulatory development of combination products (drug device products).
Dr. Ralf Hess supports Entourage as Principal Consultant IVD.

Anastasia Wolf

Principal Project Consultant

Anastasia Wolf studied Biopharmaceutical Technology at the Technische Hochschule Mittelhessen in Giessen and graduated with a Bachelor of Science in 2015.
Ms. Wolf worked for a global player in in-vitro diagnostics and was Head of Technical Documentation Regulatory Affairs. She has knowledge of technical documentation, the implementation of international approvals, IEC 62304 medical device software, conformity assessments and data management. Ms. Wolf rounds off her profile with her excellent language skills in German, Russian and English.
Anastasia Wolf supports Entourage as Principal Project Consultant.

Newsletter.

Read more.

GMP: EMA distant assessments - Europe - and not America - First!
The European Medicines Agency finds a solution that allows performing ...
Digital revolution in the laboratory environment.
The laboratory of the future is digital. This article shows how ...
Human monoclonal therapeutic antibodies based on plant systems for human use.
Is the next generation of therapeutic monoclonal antibodies tobacco plant-derived?
COVID-19: "Renaissance" of Small Molecules.
Research into a drug to combat SARS-CoV-2 leaves the Small ...
MDR postponed. By EU. Because of Corona.
Due to the SARS-CoV-2 pandemic, the EU has proposed to extend the ...